Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Roche Holding AG A global leader in pharmaceuticals and diagnostics, pioneering personalized healthcare solutions.	Switzerland	RO
ROCKET PHARMACEUTICALS, INC. Developing LV/AAV gene therapies for rare genetic bone marrow and cardiovascular diseases.	United States of America	RCKT
ROHTO PHARMACEUTICAL CO.,LTD. Manufactures OTC drugs, skincare, and cosmetics with a focus on eye and dermatological health.	Japan	4527
Roivant Sciences Ltd. Accelerates medicine and tech development by building agile, focused subsidiary companies.	United States of America	ROIV
RPbio Inc. A global CDMO specializing in soft capsules, pharmaceuticals, and health functional foods.	South Korea	314140
RTA LABORATUVARLARI BİYOLOJİK ÜRÜNLER İLAÇ VE MAKİNE SANAYİ TİCARET A.Ş. Develops and produces IVD kits and biological pharmaceuticals for the healthcare sector.	Türkiye	RTALB
RYTHM, Inc. Manages cannabis & hemp brands offering full-spectrum flower, vapes, and beverages.	United States of America	RYM
SAB Biotherapeutics, Inc. Develops human polyclonal antibodies for autoimmune disorders and infectious diseases.	United States of America	SABS
Sagimet Biosciences Inc. Clinical-stage biopharma developing FASN inhibitors for MASH, acne, and cancer.	United States of America	SGMT
SAMIL PHARMACEUTICAL CO.,LTD Develops & manufactures drugs for eye & liver diseases, with a broad portfolio & CDMO services.	South Korea	000520